Published in Vaccine Weekly, November 6th, 2002
The trial involved 10 HIV infected individuals who were treated over 6 years with an innovative therapy developed by BioDelivery Sciences International, Inc. (Nasdaq: BDSI; BDSIW). The treatment is based on the person's own virus and cells and is designed to stimulate a different and stronger immune response to the specific virus subtypes with which they are infected.
At the end of the study, results showed no progression of the disease in any of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly